Pfizer, BioNTech get vaccine 'fast track' from FDA

Pfizer and its German partner BioNTech on Monday announced two of their experimental coronavirus vaccines received 'fast track' designation from the U.S. Food and Drug Administration.

...meaning the FDA may decide on an approval within six months.

If a vaccine candidate gets the green light, the companies said they expect to make up to 100 million doses by the end of this year.

The companies said the recent testing of an experimental vaccine on 24 healthy volunteers showed that after 28 days they had developed higher levels of COVID-19 antibodies than typically seen in infected people.

Upon regulatory approval, the companies expect to start a large trial with up to 30,000 participants… possibly later this month - paving the way toward a potential release of a vaccine.

The U.S. and other countries have poured billions into developing a safe and effective vaccine for COVID-19. As of now - none are approved.

Video Transcript

- Pfizer and its German partner BioNTech on Monday announced two of their experimental coronavirus vaccines received fast-track designation from the US Food and Drug Administration, meaning the FDA may decide on an approval within six months. If a vaccine candidate gets the green light, the companies said they expect to make up to 100 million doses by the end of this year.

The companies said the recent testing of an experimental vaccine on 24 healthy volunteers showed that after 28 days, they had developed higher levels of COVID-19 antibodies than typically seen in infected people. Under regulatory approval, the companies expect to start a large trial with up to 30,000 participants possibly later this month, paving the way toward a potential release of a vaccine. The US and other countries have poured billions of dollars into developing a safe and effective vaccine for COVID-19. As of now, none are approved.